Objective
Multidrug resistance of Mycobacterium tuberculosis is declared a serious global threat by the World Health Organization.
Our project aims at developing a comprehensive model of molecular mechanisms responsible for antimicrobial drug resistance of tuberculosis. Isoniazid is the main drug used for TB treatment, because it interacts with the bacterial catalase
that leads to the bacterial death. The library of isoniazid resistant strains (over 100 different strains) will be used as
experimental basis for building theoretical and computational models of the molecular processes leading to drug resistance
of mutated bacteria. The model will be used for suggesting effective treatment targeting these mechanisms and overcoming
the resistance.
AMR-TB RISE will be used to utilise the expertise of highly specialised research groups of biologists, clinicians, biochemists,
physicists, computer engineers, and mathematicians allowing the researches from these groups to work in multiple
laboratories of the Consortium all over the world. Particular attention will be given to training the next generation of young
researcher and forming tightly interconnected, long term collaboration devoted to solving the pressing global problem of antimicrobial resistance not only in TB, but in a wide spectrum of diseases.
Fields of science
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Call for proposal
H2020-MSCA-RISE-2018
See other projects for this call
Coordinator
B4 7ET Birmingham
United Kingdom
Participants (5)
01601 Kyiv
01033 Kyiv
28006 Madrid
GU2 7XH Guildford
98122 Messina
Partners (5)
193063 Saint Petersburg
199034 Saint Petersburg
305000 Kursk
351 0198 Wako Shi Saitama
17012759 Quito